-
公开(公告)号：KR102203334B1
公开(公告)日：2021-01-15
申请号：KR1020190042935
申请日：2019-04-12
Applicant: 성균관대학교산학협력단
IPC: A61K31/454 , A61K31/357 , A61P35/00
Abstract: 본발명은피모자이드(pimozide)를유효성분으로포함하는항암보조제에관한것으로서, 상기피모자이드는항암제에대한감수성을증진시키는효과가있어, 항암제와병용투여한경우암세포또는다중약물내성암세포의세포사멸을증가시킴으로써, 특히, 항암제내성암의치료에유용하게사용할수 있다.
-
公开(公告)号：KR1020130020085A
公开(公告)日：2013-02-27
申请号：KR1020110082481
申请日：2011-08-18
Applicant: 성균관대학교산학협력단 , 대한민국 (식품의약품안전처장)
IPC: G01N33/493 , G01N33/15 , G01N33/48
CPC classification number: G01N33/493 , G01N33/00 , G01N33/15 , G01N33/48
Abstract: PURPOSE: A method for discriminating nephrotoxicity of a drug and a method for screening a nephrotoxicity-inducing material are provided to accurately determine nephrotoxicity with high sensitivity and specificity. CONSTITUTION: A method for determining nephrotoxicity of a drug comprises: a step of measuring concentration 1 of acetate and dimethyl glycine contained in urine from a drug-injected individual; a step of comparing concentration 1 with concentration 2 of acetate and dimethyl glycine contained in urine from a control group; and a step of determining whether concentration 1 is significantly changed. A method for screening a nephrotoxicity-inducing material comprises: a step of injecting a test composition or a test compound into an individual as an experimental group; a step of measuring and comparing the concentration of acetate and dimethyl glycine contained in urine from a control group; and a step of selecting a test composition or test compound which significantly changes the concentration of acetate and dimethyl glycine compared with the control group.
Abstract translation: 目的：提供用于鉴别药物肾毒性的方法和筛选肾毒性诱导物质的方法，以高灵敏度和特异性精确测定肾毒性。 构成：测定药物的肾毒性的方法，其特征在于，测定来自药物注射个体的尿液中所含的乙酸盐和二甲基甘氨酸的浓度1的步骤。 从对照组中比较浓缩物1与尿液中所含的乙酸盐和二甲基甘氨酸的浓度2的步骤; 以及确定浓度1是否显着改变的步骤。 筛选肾毒性诱导材料的方法包括：将试验组合物或试验化合物作为实验组注入个体的步骤; 测量和比较对照组尿液中所含的乙酸盐和二甲基甘氨酸的浓度的步骤; 以及与对照组相比，选择显着改变乙酸盐和二甲基甘氨酸浓度的测试组合物或测试化合物的步骤。
-
公开(公告)号：KR102000201B1
公开(公告)日：2019-07-22
申请号：KR1020170096491
申请日：2017-07-28
Applicant: 성균관대학교산학협력단
IPC: C07D333/36 , A61K31/381 , C07C235/84
-
4.发明授权항염증 활성을 갖는 플라보노이드계 화합물을 유효성분으로 하는 염증질환 예방 또는 치료용 약학조성물 및 이의 합성방법 有权用于预防或治疗含有具有抗炎活性的类黄酮化合物的活性成分的炎性疾病的药物组合物及其合成方法
公开(公告)号：KR101763315B1
公开(公告)日：2017-07-31
申请号：KR1020160033946
申请日：2016-03-22
Applicant: 성균관대학교산학협력단
IPC: A61K31/352 , A61K36/185 , C07D311/28
Abstract: 고시페틴은자연화합물로, 히비스커스의꽃받침(calyx of)로부터유래한다. 본발명에따른화학식 1의화합물로 Raw 264.7 세포를처리한후, 상기세포의면역적활성효과를분석및 비교하였다. 그결과본 발명에따른신규한플라보노이드계화합물로처리한 Raw 264.7 세포로부터염증반응경로(inflammasome pathway)를활성화하는 NLRP3과 NF-kB의발현이상당히억제되었음을확인할수 있었다. 이러한결과를통해, 본발명에따른신규한플라보노이드계화합물이대식세포에서의염증매개물질과인플라마솜을저해하고, 이와관련된 TNF-α와 IL-1β의분비도억제한다는것을확인하였다. 따라서본 발명의실험예에서와같이본 발명에따른신규한플라보노이드계화합물이 LPS로처리되어염증활성이유발된세포에서의염증질환발현에대해, 종래고시페틴화합물보다우수한항염증효과를갖는다는것을확인하였다.
Abstract translation: 棉酚是一种天然化合物，衍生自芙蓉花萼。 在用本发明的式1化合物处理Raw264.7细胞后，分析和比较细胞的免疫活性。 其结果NLRP3激活脱离本发明的炎症反应路径（炎性途径），一个的RAW 264.7细胞以新颖的类黄酮系化合物根据字符串和NF-kB的是uibal可确认非常抑制处理。 通过这些结果，可以确认，抑制新颖类黄酮化合物yidaesik细胞eseoui炎症介质和根据本发明及其相关的TNF-α和IL-1β的抑制非分钟peulrama棉花。 因此确认，本发明eseoui的新颖的类黄酮化合物与LPS炎症活动诱导的细胞炎性疾病表达了根据本发明处理，如图中的实验例，它具有比现有通知佩廷化合物优异的抗炎作用 这是。
-
Patent Agency Ranking
公开(公告)号：KR100702519B1
公开(公告)日：2007-04-02
申请号：KR1020050043715
申请日：2005-05-24
Applicant: 성균관대학교산학협력단
Abstract: 본 발명은 애기닥나무 추출물을 포함하는 미백용 조성물에 관한 것으로, 상기 조성물은 피부미백 목적의 화장품, 의약품 및 식품에 사용될 수 있다.
애기닥나무, 추출물, 미백효과, 타이로시나제, 멜라닌,-
-
公开(公告)号：KR1020130020086A
公开(公告)日：2013-02-27
申请号：KR1020110082482
申请日：2011-08-18
Applicant: 성균관대학교산학협력단 , 대한민국 (식품의약품안전처장)
IPC: G01N33/493 , G01N33/15 , G01N33/48
CPC classification number: G01N33/493 , G01N33/00 , G01N33/15 , G01N33/48
Abstract: PURPOSE: A method for determining nephrotoxicity using concentration change of acetate and trimethylamine-N-oxide(TMAO) contained in urine is provided to ensure high sensitivity and specificity. CONSTITUTION: A method for determining nephrotoxicity of a drug comprises: a step of measuring the concentration 1 of acetate and trimethylamine-N-oxide(TMAO) contained in urine which is injected with a drug; a step of comparing the concentration 2 of acetate and TMAO contained in urine from a control group; and a step of determining whether the concentration 1 is significantly changed.
Abstract translation: 目的：提供使用尿中含有的乙酸盐和三甲胺-N-氧化物（TMAO）的浓度变化来确定肾毒性的方法，以确保高灵敏度和特异性。 构成：测定药物的肾毒性的方法，包括：测定注射有药物的尿中含有的乙酸盐和三甲胺-N-氧化物（TMAO）的浓度1的步骤; 从对照组中比较尿中含有的乙酸盐浓度2和TMAO的步骤; 以及确定浓度1是否显着变化的步骤。
-
公开(公告)号：KR1020130020084A
公开(公告)日：2013-02-27
申请号：KR1020110082480
申请日：2011-08-18
Applicant: 성균관대학교산학협력단 , 대한민국 (식품의약품안전처장)
IPC: G01N33/493 , G01N33/15 , G01N33/48
CPC classification number: G01N33/493 , G01N33/00 , G01N33/15 , G01N33/48
Abstract: PURPOSE: A method for determining nephrotoxicity of a drug using concentration change of acetate and citrate contained in urine is provided to ensure high sensitivity and specificity and to develop a safety novel drug. CONSTITUTION: A method for determining nephrotoxicity of a drug comprises: a step of measuring the concentration 1 of acetate and citrate contained in urine from a drug-injected individual; a step of comparing the concentration 1 with the concentration 2 of acetate and citrate contained in urine from a control group; and a step of determining whether the concentration 1 is significantly changed. The individual is a mammal exclusive of humans.
Abstract translation: 目的：提供使用尿中含有的醋酸盐和柠檬酸盐浓度变化来确定药物的肾毒性的方法，以确保高灵敏度和特异性，并开发出安全新型药物。 构成：测定药物的肾毒性的方法，包括：测定来自药物注射个体的尿液中所含的乙酸盐和柠檬酸盐的浓度1的步骤; 比较浓度1与来自对照组的尿液中所含的乙酸盐和柠檬酸的浓度2的步骤; 以及确定浓度1是否显着变化的步骤。 个人是不属于人类的哺乳动物。
-
公开(公告)号：KR1020060121496A
公开(公告)日：2006-11-29
申请号：KR1020050043715
申请日：2005-05-24
Applicant: 성균관대학교산학협력단
Abstract: A skin-whitening composition comprising the extract of Broussonetia kazinoki var. humilis is provided to develop the novel skin-whitening composition having improved skin-whitening activity and reduced side effects by using natural products. The skin-whitening composition comprises the extract of Broussonetia kazinoki var. humilis as an effective ingredient, wherein the extract of Broussonetia kazinoki var. humilis is prepared by extracting Broussonetia kazinoki var. humilis with water or organic solvent at room temperature or increased temperature; and the composition is applied to cosmetics having formulation of soft lotion, nutrition lotion, nutrition cream, massage cream, essence, pack or powder, medicines or food.
Abstract translation: 一种皮肤美白组合物，其包含布鲁氏菌（Broussonetia kazinoki var。 提供humilis以开发出具有改善的皮肤美白活性和通过使用天然产物减少副作用的新型皮肤美白组合物。 皮肤美白组合物包含布鲁氏菌（Broussonetia kazinoki var。）的提取物。 胡椒粉作为有效成分，其中布鲁氏菌属的提取物 胡椒粉通过提取布鲁氏菌（Broussonetia kazinoki var。 在室温或升高的温度下用水或有机溶剂干燥; 并且该组合物应用于具有柔软洗剂，营养洗剂，营养霜，按摩霜，精华，包装或粉末，药物或食品的配方的化妆品。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.02 seconds)
